(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of -16.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 119.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.3%.
Sarepta Therapeutics's revenue in 2026 is $2,413,715,000.On average, 28 Wall Street analysts forecast SRPT's revenue for 2026 to be $170,593,540,436, with the lowest SRPT revenue forecast at $136,223,343,100, and the highest SRPT revenue forecast at $245,935,527,889. On average, 21 Wall Street analysts forecast SRPT's revenue for 2027 to be $162,524,927,037, with the lowest SRPT revenue forecast at $118,199,946,936, and the highest SRPT revenue forecast at $206,221,184,016.
In 2028, SRPT is forecast to generate $146,806,848,987 in revenue, with the lowest revenue forecast at $70,816,228,846 and the highest revenue forecast at $184,425,449,120.